







an Open Access Journal by MDPI

# **Molecular Profiling of Lung Cancer**

Guest Editor:

#### Dr. Kentaro Inamura

Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan

Deadline for manuscript submissions:

closed (30 June 2019)

## **Message from the Guest Editor**

Dear Colleagues,

High-throughput technologies have enabled the molecular profiling of lung cancer, allowing for refined risk assessments, as well as the development of non-invasive screening methods or therapeutic interventions for lung cancer. The objective of this Special Issue is to publish the latest findings in the molecular profiling/signatures of lung cancer aimed toward clinical implementation.

Topics of this Special Issue include, but are not limited to:

- Molecular profiling/signatures that can classify lung cancers into specific subtypes with different clinical outcomes or sensitivities to specific treatments.
- Molecular profiling/signatures that allow the determination of useful biomarkers for liquid biopsy.
- Molecular profiling/signatures that allow the determination of biomarkers for acquired resistance to specific drugs.

Target topics (examples are described above) are comprehensive and will give a thorough view of the increasing knowledge of molecular profiling/signatures of lung cancer.

Dr. Kentaro Inamura *Guest Editor* 













an Open Access Journal by MDPI

### **Editor-in-Chief**

#### Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

## **Message from the Editor-in-Chief**

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

#### **Contact Us**